Objective. HLA-B27-associated spondyloarthritides are associated with an altered intestinal microbiota and bowel inflammation. We undertook this study to identify HLA-B27-dependent changes in both host and microbial metabolites in the HLA-B27/b 2 -microglobulin (b 2 m)-transgenic rat and to determine whether microbiota-derived metabolites could impact disease in this major model of spondyloarthritis.
(CD) and ulcerative colitis, as well as in extraintestinal inflammatory diseases, including arthritis, diabetes mellitus, and multiple sclerosis (for review, see refs. 1 and 2). Recently, it has been established that dysbiosis may be accompanied by a profound change to the metabolic profile of the gut, including alterations in microbial metabolites such as short-chain fatty acids (SCFAs) and trimethylamine N-oxide, which are bioactive mediators that modulate host physiology (for review, see ref. 3) .
The HLA-B27/b 2 -microglobulin (b 2 m)-transgenic rat is the foremost translational model of spondyloarthritis (SpA). These animals express multiple copies of human HLA-B27 in association with the b 2 m heavy chain (4) . HLA-B27 is the gene with the strongest known genetic association with SpA. These animals model human SpA, with the development of peripheral arthritis, psoriasis, and bowel inflammation to varying degrees contingent on the copy number of this transgene in addition to rat background (5) . We have shown previously that HLA-B27 expression significantly alters the intestinal microbiota in this model (6, 7) , mirroring parallel reports that SpA patient populations exhibit a dysbiotic gut phenotype (8) (9) (10) . These findings complement prior animal and clinical studies that strongly implicate the intestinal microbiota in SpA pathogenesis (for review, see ref. 11 ).
In the present study, we assessed the impact of HLA-B27 expression on the gut metabolome in this rat model of SpA. We found that multiple metabolite families were significantly altered by HLA-B27 expression, including amino acids, lipids, carbohydrates, and xenobiotics. Among the most significantly altered were medium-chain fatty acids (MCFAs) and SCFAs. Strikingly, treatment of HLA-B27/b 2 m-transgenic rats with the SCFA propionate significantly attenuated HLA-B27-associated inflammatory disease. These findings establish a functional link between HLA-B27 expression, an altered gut metabolome, and the pathogenesis of SpA-like disease.
MATERIALS AND METHODS
Ethics statement. All animal experiments were performed according to the experimental and ethical standards of the Association for Assessment and Accreditation of Laboratory Animal Care International and the Oregon Health and Science University (OHSU) Institutional Animal Care and Use Committee.
Animals. We maintained a colony of Fischer 33-3 HLA-B27/b 2 m hemizygous rats as described previously (7) . Briefly, hemizygous female rats were crossed with wild-type (WT) Fischer 344 male rats to produce HLA-B27/b 2 mtransgenic rats and littermate controls. Animals were singly housed and maintained under specific pathogen-free conditions. All animals were fed a diet of standard laboratory chow (LabDiet). All animal groups included males and females, with age/sex matching between groups.
Sample collection. Animals were euthanized at the indicated ages/time points by CO 2 asphyxiation and cervical dislocation. Cecal contents (;1 ml) and cecal and colonic tissue (;50 mg) were snap-frozen and stored at 2808C prior to subsequent analysis. Snap-frozen colonic tissue was collected from mid colon. For cell isolation experiments, intestinal tissue, mesenteric lymph nodes (MLNs), and spleen were collected into phosphate buffered saline/0.1% bovine serum albumin and stored on ice prior to subsequent processing. For histology, longitudinal sections of cecum and ;1-cm cross-sections of proximal, mid, and distal colon were fixed in 10% neutral buffered formalin.
Metabolomic profiling of the gut. Cecal content samples were analyzed using an HD4 platform (Metabolon). Briefly, samples were prepared using an automated Microlab STAR system from Hamilton (for further details, see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40183/abstract). To remove protein and dissociate small molecules bound to protein, samples were precipitated with methanol and centrifuged, and extract was divided for ultraperformance liquid chromatography tandem mass spectrometry (MS) analysis and gas chromatography (GC)-MS analysis.
The GC-MS metabolite screen was performed using a Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer (Thermo Electron Corporation) using electron impact ionization and operated at unit mass resolving power. The instrument had a mass/charge scan range of 50-750.
SCFA analysis. SCFAs were measured by GC-MS at the Bioanalytical Shared Resource/Pharmacokinetics Core facility at OHSU (see Supplementary Methods).
SCFA treatment. Six-week-old HLA-B27/b 2 m-transgenic rats or WT controls were administered either sodium propionate (150 mM) or sodium butyrate (150 mM) ad libitum in drinking water throughout the experiment. Animals were necropsied at age 16 weeks. These doses and this route of administration were selected based on previously reported in vivo studies (12, 13) .
Histology and disease scoring. Formalin-fixed intestinal tissues were embedded in paraffin, sectioned to 5 mm, and stained with hematoxylin and eosin. Scoring of intestinal inflammation was performed using a semiquantitative scoring system (0-12) as described previously (7) . Briefly, this 4-parameter scoring system includes epithelial hyperplasia, goblet cell numbers, leukocytic infiltrate, and markers of severe inflammation (e.g., submucosal inflammation, abscesses, or ulceration). Each parameter is scored 0-3, with the total cecum score and mean colon score (for the 3 colon sections collected) shown for each animal. By the final time point of 16 weeks used in our study, animals had not presented with either psoriasis or arthritis, which typically develops at .20 weeks in the Fischer 344 33-3 HLA-B27/b 2 m-transgenic line.
Analysis of intestinal gene expression. Briefly, RNA was extracted from intestinal tissue using TRIzol reagent (Ambion) and reverse transcribed into complementary DNA (cDNA) using a High Capacity cDNA Reverse Transcription kit (Life Technologies). For quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis of interleukin-17A (IL-17A), interferon-g (IFNg), and IL-1b, we used published primer sequences and RT 2 SYBR Green qPCR Master Mix (Qiagen) as described previously (7) . For all other qRT-PCR analyses, we used TaqMan Gene Expression Assays (Life Technologies) in conjunction with Maxima Probe qPCR Master Mix (Thermo Scientific). Samples' hypoxanthine guanine phosphoribosyltransferase controls were prepared for both qRT-PCR chemistries for the purpose of normalization. For further details (including primer details), (see Supplementary Methods).
Analysis of immune cells by flow cytometry. Suspensions of spleen and MLN cells were prepared as described previously (14) . Cecal and colonic lamina propria lymphocytes were isolated by EDTA digestion, collagenase/DNase treatment, and Percoll gradient as described previously (7) . Cells were then surface-stained for 20 minutes on ice with AQUA Live/Dead stain (Invitrogen), PerCP-Cy5.5-conjugated anti-rat CD4 (BioLegend), and phycoerythrin-conjugated anti-rat T cell receptor b (BD Biosciences), and then FoxP3 staining was performed using a FoxP3 staining kit (eBioscience) in accordance with the manufacturer's instructions using allophycocyaninconjugated anti-rat/mouse FoxP3 (eBioscience). Cells were acquired on a BD Fortessa instrument (BD Biosciences) and analyzed using FlowJo software.
Statistical analysis. Details of the statistical analysis used for our metabolomic screen, see Supplementary Methods, available online at http://onlinelibrary.wiley.com/doi/10.1002/ art.40183/abstract. For analysis of individual metabolite levels from our screen, data were normalized to an equivalent of 2 mg dry weight of cecal material per sample and logtransformed prior to application of Welch's unpaired t-test (which does not assume equal variances) with subsequent Benjamini-Hochberg correction to account for multiple comparisons, and a false discovery rate of 0.2 was applied. For samples obtained from 6-week-old animals, the least abundant 20% of metabolites (median abundance for each metabolite across the data set, irrespective of genotype or fold difference) were removed prior to this analysis. For comparison of histologic scores, gene expression, immune cell frequencies, and cecal SCFA concentrations between untreated and SCFA-treated animals or between WT and HLA-B27/b 2 m-transgenic animals, the nonparametric Mann-Whitney U test was used unless specified otherwise. All statistical analysis was performed using the R package (www.r-project.org) or GraphPad Prism software.
RESULTS
Significant alteration of the intestinal metabolome by HLA-B27 expression. To establish the impact of HLA-B27 expression on the intestinal metabolome, we performed metabolomic profiling of cecal contents from HLA-B27/b 2 m-transgenic rats and WT controls at age 6 weeks and at age 16 weeks, representing animals before disease and those with established disease, respectively. Our metabolite screen identified 582 named biochemicals in cecal contents. Using analysis of variance with a P value threshold of 0.05 to initially compare groups, we found that 188 metabolites were upregulated in 16-week-old HLA-B27/b 2 m-transgenic animals relative to WT littermate controls, and 66 were down-regulated (see Supplementary Data, available at http://onlinelibrary.wiley.com/doi/10.1002/art.40183/ abstract), indicating that HLA-B27/b 2 m-transgenic rats have a profoundly altered intestinal metabolome. In addition to these changes in rats with established disease, 52 metabolites were up-regulated and 11 were downregulated in 6-week-old transgenic rats relative to agematched controls. These differences were visualized by hierarchical cluster analysis ( Figure 1A ), which demonstrated the global metabolic shifts in 16-week-old HLA-B27/b 2 m-transgenic animals in addition to more moderate changes in 6-week-old animals (before disease).
To further examine metabolic shifts driven by HLA-B27 expression, we also performed pathway enrichment analysis (15) to identify biochemical pathways that were strongly influenced by HLA-B27 expression ( Figures 1B and C) . Notably, HLA-B27 expression impacted metabolites involved in numerous biochemical pathways, including those associated with amino acid, carbohydrate, lipid, and xenobiotic metabolism. When we examined both 6-week ( Figure 1B ) and 16-week ( Figure 1C ) time points, a number of these enriched pathways were shared at both time points, including glycine, serine, and threonine metabolism; aminosugar metabolism; MCFA metabolism; fructose, mannose, and galactose metabolism; and phenylalanine and tyrosine metabolism. We noted, however, that some affected metabolite pathways were only observed at 1 time point, for instance, gamma glutamyl amino acids at the 6-week time point ( Figure 1B ; also see Supplementary Figure 1 , available at http://onlinelibrary.wiley.com/doi/10.1002/ art.40183/abstract) or food component/plant and secondary bile acid metabolism at the 16-week time point ( Figure 1C ). These may point to evolving disturbances of the intestinal metabolome over time induced by HLA-B27 expression.
Microbial fermentation products significantly impacted by HLA-B27 expression. In light of the large number of metabolites detected in our screen of cecal contents, and given our relatively restricted sample size (n 5 8 animals per genotype per age group), we were unable to identify any individual metabolites that exhibited differential abundance in 6-week-old animals that attained statistical significance when we adjusted stringently for multiple comparisons across the entire data set. However, after removal of low-abundance metabolites (the lowest 20%), we observed 5 metabolites that exhibited a significantly higher abundance in HLA-B27/b 2 m-transgenic animals than in WT controls ( Figure 2A ). We did not observe any significantly downregulated individual metabolites at this time point. The 1986 ASQUITH ET AL up-regulated metabolites ( Figure 2A ) were histidine and tyrosine (amino acids), spermidine (a polyamine), Nacetylmuramate (a microbial cell wall component), and glycerate (a sugar). Histidine, spermidine, and glycerate were also elevated at 16 weeks (see Supplementary  Figure 2A , available at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40183/abstract), indicating that metabolomic changes detected in established disease may also be detected before disease. Interestingly, however, while Nacetylmuramate and tyrosine were elevated at 6 weeks in HLA-B27/b 2 m-transgenic animals, they were significantly decreased once disease was established at 16 weeks (see Supplementary Figure 2 ). Our subsequent analysis focused on the 16-week data set, which had a large number of individual metabolites that were significantly impacted by HLA-B27 expression (see Supplementary Table 1 , available at http://onlinelibrary.wiley.com/doi/10.1002/art.40183/ abstract). We have shown previously that HLA-B27 expression is accompanied by a marked expansion of the mucin-degrading bacterium Akkermansia muciniphila (6,7). We therefore examined the abundance of mucus components identified in our metabolomic screen. Strikingly, the mucus carbohydrates fucose and galactose were dramatically increased in the cecum of HLA-B27/b 2 m-transgenic animals ( Figure 2B ). The mucus aminosugar galactosamine and the sialic acids Nacetylneuraminate and N-acetylglucosamine were also increased in HLA-B27/b 2 m-transgenic animals ( Figure  2B ). In contrast, the mucus aminosugar glucosamine was unchanged. In addition to this major host-derived microbial energy source, we also examined dietary components and their microbially derived metabolites ( Figure 2C ). The isoflavones daidzein, naringenin, and apigenin are flavonoid phytophenols present in soy and other plants, and they were significantly increased in 
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HLA-B27/b 2 m-transgenic animals ( Figure 2C ). In contrast, equol, a microbial derivative of daidzein, was significantly decreased. Enterolactone, a mammalian lignin formed by the action of intestinal bacteria on dietary plant lignans, was also significantly decreased ( Figure 2C ). Taken together, the liberation of mucus components and the decrease in some plant-derived metabolites (but with increased precursors) may indicate markedly shifted metabolic function by the intestinal microbiota in HLA-B27/b 2 m-transgenic animals.
We also found a number of metabolites indicative of an active inflammatory response that were significantly up-regulated in intestinal contents of HLA-B27/ b 2 m-transgenic animals. These included the tryptophan derivatives kynurenine and N-acetylkynurenine, which are downstream metabolites of indoleamine 2,3-dioxygenase activity ( Figure 2C ). Elevated lactate levels are also a hallmark of intestinal inflammation and were likewise significantly increased at 16 weeks in HLA-B27/ b 2 m-transgenic animals ( Figure 2C) . Interestingly, the microbial metabolite p-cresol sulfate, a product of proteolytic fermentation, was also highly increased in HLA-B27/b 2 m-transgenic animals. This metabolite is associated with inflammation and oxidative stress.
Bile acid metabolism, in particular the conversion of primary to secondary bile acids, is another major functional role of the intestinal microbiota. Examination of bile acids in our metabolomic analysis determined that cholesterol and several bile acids were significantly impacted by HLA-B27 expression ( Figure 2D ). Interestingly, cholesterol and the primary bile acids a-muricholate and cholate were significantly increased in HLA-B27/b 2 mtransgenic animals, while the secondary bile acid metabolites 3b-hydroxy-5-cholenoic acid, 6-b-hydroxylithocholate, 6-oxolithocholate, dehydrolithocholate, deoxycholate, hyocholate, and hyodeoxycholate were all significantly decreased. Only 2 bile acids, 7-ketolithocholate and ursodeoxycholate, were significantly increased in HLA-B27/b 2 m-transgenic animals. Taken together, these findings further indicate that HLA-B27 expression broadly impacts the levels of microbially derived metabolites in the gut.
Association of HLA-B27 expression with altered levels of MCFAs and SCFAs. Our prior pathway enrichment analysis had identified MCFAs as one of the metabolite pathways most impacted by HLA-B27 expression in 16-week-old HLA-B27/b 2 m-transgenic animals ( Figure 1C ). In light of this, we further examined MCFA levels in transgenic rats and WT controls ( Figure 3A) . Strikingly, the MCFAs caproic (C6 hexanoic) acid and enanthic (C7 heptanoic) acid were significantly reduced in HLA-B27/b 2 m-transgenic animals at 16 weeks. Of note, levels of the MCFAs caprylic Figure 3 . Significant impact of HLA-B27 expression on intestinal levels of medium-chain fatty acids (MCFAs) and short-chain fatty acids (SCFAs) at 6 weeks and 16 weeks. A, Levels of MCFAs in cecal contents of wild-type (WT) rats and HLA-B27/b 2 -microglobulin-transgenic (TG) rats, as measured by ultra-performance liquid chromatography tandem mass spectrometry metabolomic screen. Values are the mean 6 SEM (n 5 8 rats per group). * 5 P , 0.2; *** 5 P , 0.05 (Benjamini-Hochberg-corrected P values with a false discovery rate of 0.2 instead of conventional P values). B, Cecal concentration of the SCFAs acetate, propionate, butyrate, and valerate, as determined by gas chromatography mass spectrometry. Values are the mean 6 SEM (n 5 6-8 rats per group). * 5 P , 0.05; ** 5 P , 0.01 by Mann-Whitney U test.
(C8 octanoic) acid and capric (C10 decanoic) acid also trended in the same direction (levels of capric acid decreased significantly prior to Benjamini-Hochberg correction for multiple comparisons). This trend toward lower MCFA levels was also seen in 6-week-old HLA-B27/b 2 m-transgenic animals ( Figure 3A) .
SCFAs are soluble, low molecular weight metabolites that are major microbial fermentation products of dietary fiber and include acetate, propionate, butyrate, and valerate. Since these small molecules were not readily detected by our metabolomic analysis, we performed targeted GC-MS on cecal contents from HLA-B27/b 2 m-transgenic and control rats to measure levels of these metabolites ( Figure 3B ). Validating this approach, we also confirmed that production of these metabolites was critically dependent on the gut microbiota, since antibiotic depletion of the gut microbiota with vancomycin dramatically reduced cecal SCFA levels (see Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40183/abstract). Interestingly, SCFAs also showed HLA-B27-dependent differences, although with more variability than MCFAs. For instance, at 6 weeks (before disease), valerate was significantly increased in HLA-B27/b 2 m-transgenic animals versus controls, although levels of valerate were significantly lower in HLA-B27/b 2 m-transgenic animals than in controls at the 16-week time point ( Figure 3B ). Other changes observed were a significant increase in butyrate concentration at 6 weeks and a significant increase in propionate concentration at 16 weeks ( Figure 3B ). Taken together, these findings indicate that HLA-B27 expression leads to altered metabolism of several intestinal fatty acids.
The microbial metabolite propionate functionally impacts HLA-B27-associated inflammation. Since HLA-B27 expression clearly impacted the intestinal Figure 4 . Administration of the short-chain fatty acid sodium propionate (Pr) significantly attenuates HLA-B27-associated immune pathology. Sixweek-old HLA-B27/b 2 -microglobulin (b 2 m)-transgenic rats or wild-type (WT) littermate controls were left untreated (-) or were treated with either sodium propionate (150 mM) or sodium butyrate (Bu; 150 mM) in drinking water for 12 weeks. At necropsy (16 weeks), the cecum and colon were harvested for analysis of intestinal inflammation. A, Histologic assessment of intestinal inflammation in the cecum and colon by semiquantitative scoring system. B, Relative expression of mRNA for interleukin-1b (IL-1b), IL-17A, and interferon-g (IFNg) in colon tissue. All mRNA expression data were normalized to hypoxanthine guanine phosphoribosyltransferase (HPRT). Symbols represent individual animals; bars show the mean. Data are representative of 3 pooled independent experiments. * 5 P , 0.05; ** 5 P , 0.01; *** 5 P , 0.005 by Mann-Whitney U test. metabolome, we were eager to determine whether microbial metabolites specifically could modify SpA pathogenesis. In light of the large number of HLA-B27-dependent metabolites, we selected the SCFAs propionate and butyrate for in vivo functional analysis since they have low toxicity, are commercially available, and are reported to have immunomodulatory functions. We therefore administered propionate or butyrate (150 mM) in drinking water to 6-week-old rats (before disease) for 10 weeks, and we examined markers of HLA-B27-associated bowel inflammation (Figure 4) . Strikingly, propionate significantly reduced both cecal and colonic intestinal inflammation in HLA-B27/b 2 mtransgenic rats, as assessed both histologically and by expression of messenger RNA (mRNA) for the inflammatory mediators IL-1b, IL-17A, and IFNg (Figure 4 ). In contrast, the effect of butyrate was more subtle, with a trend toward reduced histology scores but with no impact on inflammatory cytokine expression (Figure 4) . SCFA treatment had no significant impact on body mass (see Supplementary Figure 4 , available at http:// onlinelibrary.wiley.com/doi/10.1002/art.40183/abstract).
The reported immunomodulatory properties of SCFAs include the induction of FoxP31 Treg cells and the induction of immunoregulatory cytokines in the intestine. We therefore determined the frequency of CD41FoxP31 T cells in cecum, colon, the gut-draining MLNs, and spleen following SCFA administration in HLA-B27/b 2 m-transgenic rats ( Figure 5A ). However, we did not observe a higher frequency of Treg cells at any of these sites following SCFA treatment. This effect was also not seen in WT animals without inflammation (see Supplementary Figure 5 tight junction protein zonula occludens 1 in HLA-B27/ b 2 m-transgenic rats ( Figure 5B ). We also did not find an obvious antimicrobial effect of SCFA administration that might lower microbial load in the gut and attenuate disease (see Supplementary Figure 6 , available at http://onlinelibrary.wiley.com/doi/10.1002/art. 40183/abstract).
HLA-B27 expression alters host expression of microbial metabolite receptors. In light of the beneficial effects of propionate on HLA-B27-associated inflammatory disease, despite the observation that this specific metabolite was not depleted in unmanipulated HLA-B27/b 2 m-transgenic animals versus healthy controls (Figure 3) , we hypothesized that HLA-B27 expression may alter host expression of SCFA receptors instead and hence disrupt this homeostatic feedback loop. We therefore examined intestinal expression of free fatty acid receptor 2 (FFAR2)/Gpr41 (a receptor that binds C2-C4 SCFAs with similar affinity), FFAR3/Gpr43 (a receptor with high affinity for propionate), and the butyrate receptor niacin receptor 1 (NIACR1)/Gpr109 ( Figure 6 ). Strikingly, we found that HLA-B27 expression impacted intestinal expression of mRNA for several SCFA receptors, with significantly decreased cecal expression of the propionate receptor FFAR3 in contrast to increased expression of FFAR2 and NIACR1 at age 16 weeks (Figure 6A ). This specific reduction in FFAR3 expression was also observed in 6-week-old (before disease) animals (Figure 6B) . Significantly reduced expression of mRNA for FFAR3 was also observed in colon (see Supplementary  Figure 7 , available at http://onlinelibrary.wiley.com/ doi/10.1002/art.40183/abstract). These findings indicate that HLA-B27 expression not only profoundly alters the intestinal metabolome, but also is associated with altered expression of host receptors that bind microbial metabolites.
DISCUSSION
Mounting evidence indicates that the intestinal microbiota may play a significant role in the pathogenesis of SpA disease. A dysbiotic or altered intestinal microbiota is observed in several forms of SpA, including psoriatic arthritis, ankylosing spondylitis (AS), and juvenile enthesitis-related arthritis (8) (9) (10) , and subclinical bowel inflammation is observed in more than half of AS patients (16) . Reactive arthritis following enteric infection is another prototypical SpA family member. A dysbiotic microbiota is also observed in both the HLA-B27/b 2 m-transgenic rat model of SpA and the model of curdlan-induced inflammation in ZAP-70 mutant mice (6, 7, 17) . Depletion of the microbiota with antibiotics or the germ-free state also attenuates SpA disease in both models (17, 18) .
It is important to note that evidence of an altered microbiota (for example, the relative abundance or presence/absence of microbial species) does not necessarily mean that the functional potential of the microbiota is altered (19) . Indeed, healthy humans exhibit a high interindividual variability in the relative abundance of microbial species in the gut but appear to select species with similar enzymatic and functional potential (19) . Our study provides direct evidence, however, that the previously described dysbiotic changes observed in SpA are accompanied by functional changes in the metabolic output of the gut, including that of microbederived bioactive mediators such as SCFAs.
One of the major changes in the gut metabolic landscape appears to be the shift in nutrient utilization by the intestinal microbiota. For instance, microbial derivatives of plant fiber and isoflavones (such as enterolactone and equol) were decreased in HLA-B27/ b 2 m-transgenic animals, which indicates perturbed microbial fermentation. Interestingly, these specific microbial metabolites are estrogenic and are thought to have antiinflammatory properties (for review, see ref. 20) . In contrast, we observed that several mucus components were increased. This is consistent with the increased mucus production previously reported in the HLA-B27/b 2 m-transgenic rat (21) , as well as with the HLA-B27-dependent expansion of A muciniphila (7) or other microbes that catabolize mucus. Future studies that further address the impact of altered mucus metabolism on both host immunity and the intestinal microbiota would be highly interesting in the context of SpA pathogenesis.
Strikingly, we found that multiple metabolic pathways, even before disease, were impacted by HLA-B27 expression, and we found that a number of individual metabolites were significantly up-regulated in HLA-B27/b 2 m-transgenic animals compared with controls at the 6-week time point. This suggests that metabolic shifts in the gut may be a preceding event in SpA pathogenesis, rather than merely secondary to active bowel inflammation. Increased levels of tyrosine and histidine ( Figure 2A ) and differential usage of amino acid pathways ( Figures 1B and 2A) could reflect early changes in colonic protein fermentation or utilization by the host (22) . Polyamines such as spermidine are derived from amino acids (both by the host and the microbiota) and modulate enterocyte tight junction formation (23, 24) , secretory IgA production (25) , and mucosal maturation and repair from injury (26) and thus may strongly impact intestinal homeostasis (27) . Gamma glutamyl amino acids, a product of gamma glutamyl transferase that may be a marker of oxidative stress (28) , also appeared up-regulated at this time point ( Figure 1B ; also see Supplementary Figure 1 , available at http:// onlinelibrary.wiley.com/doi/10.1002/art.40183/abstract). Of note, HLA-B27 misfolding triggers an unfolded protein response, which may be up-regulated in the HLA-B27/b 2 m-transgenic rat and is intimately related to oxidative stress responses (29, 30) .
Beyond amino acid metabolites, we also observed altered levels of other biochemical classes even in animals before disease. We observed significantly increased glycerate levels at both age 6 weeks and age 16 weeks (Figure 2A ; also see Supplementary Figure 2 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40183/abstract). Glycerate is a simple sugar, derivatives of which are used in a panoply of metabolic pathways including glycolysis. N-acetylmuramate is a component of the microbial cell wall component peptidoglycan, and its increase may be indicative of early HLA-B27-dependent dysbiosis. Interestingly, peptidoglycan is a potent adjuvant of the innate immune system, and its systemic administration can induce both arthritis and uveitis (31) .
In light of our findings that MCFAs are reduced in the HLA-B27/b 2 m-transgenic rat model of SpA, it is notable that Scher et al reported reduced levels of the MCFAs heptanoate and hexanoate in the feces of psoriatic arthritis patients compared with those of healthy controls (8) , an observation also made in CD (32) . Indeed, the microbiota has been reported to regulate absorption of MCFAs by enterocytes and is strongly implicated in the pathogenesis of all these diseases (for review, see refs. 11 and 33). Interestingly, neither that study nor the current study found decreased levels of SCFAs; instead, we found that cecal propionate (at 16 weeks) and butyrate (at 6 weeks) concentrations were moderately elevated in HLA-B27/b 2 m-transgenic animals (Scher et al found no change in their study [8] ). This is also consistent with a previous study showing a positive correlation between cecal propionate levels and the extent of intestinal inflammation in HLA-B27/b 2 mtransgenic rats (34) . This is in contrast to CD, in which several groups have reported a reduction in intestinal SCFA concentrations (35) (36) (37) , and indicates that canonical HLA-B27-associated spondyloarthritides may have a distinct metabolomic signature compared with inflammatory bowel disease despite the degree of clinical overlap of these entities in bowel disease.
However, despite the lack of reduced SCFA production in HLA-B27/b 2 m-transgenic rats compared with controls, we found that the SCFA propionate significantly attenuated HLA-B27-dependent intestinal inflammation. This is broadly consistent with metabolic studies in which dietary supplementation with prebiotics or dietary fiber, which increase total intestinal SCFA levels, reduces intestinal inflammation in HLA-B27/ b 2 m-transgenic rats (34, 38, 39) . However, the surprising finding that propionate was elevated in luminal contents of HLA-B27/b 2 m-transgenic rats compared with controls in our study (Figure 3) indicates a considerably complex picture with respect to production of SCFAs by the microbiota and their metabolism by the host. One possibility is that higher propionate levels in the gut lumen may reflect reduced SCFA absorption or consumption by colonic enterocytes during active bowel inflammation in HLA-B27/b 2 m-transgenic rats, with a switch to MCFA utilization instead due to altered energy demand (40) . Alternatively (or in parallel), the specific inflammatory environment of the gut in SpA may create a selective pressure favoring propionateproducing bacteria that prevent the further exacerbation of local inflammation.
Reported actions of propionate include the induction of intestinal Treg cells (12, 13) , induction of regulatory cytokines (13, 41) , and improvement of barrier function (42) . However, we did not find evidence that these mechanisms were significantly impacted following propionate (or butyrate) treatment of HLA-B27/b 2 m-transgenic rats, although intestinal inflammation was significantly reduced. One possibility is that this may reflect species-specific differences in propionate activity or uptake. We note, however, that doses used in our study were highly comparable to those used in murine studies. Another possibility is that regulation of colonic cytokines and tight junction proteins is posttranslational, although unfortunately we were unable to obtain sufficient material for protein assays in the current study since intestinal tissue was used for other assays. A third possibility is that these mechanisms have largely been reported in healthy animals or in cell lines, and therefore they may have less effect in the context of HLA-B27-dependent inflammation. However, we did not find a significant induction of Treg cells by SCFA treatment even in WT animals (see Supplementary  Figure 4 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40183/abstract).
Thus, alternative mechanisms to identify the therapeutic mechanism of propionate administration warrant further scrutiny. We note that an examination of dose responses to SCFAs, their bioavailability, and their tissue absorption was not performed in the current study and would no doubt be of interest for further investigation. We recognize this limitation and we therefore cannot exclude the possibility that other SCFAs, such as butyrate, may also modulate HLA-B27-dependent inflammation at other doses or other routes of administration.
In summary, we found that HLA-B27 expression dramatically alters the intestinal metabolome. We also provide pivotal data that microbial metabolites significantly impact the development of HLA-B27-associated inflammatory disease. While our study examined HLA-B27-associated bowel inflammation, it would obviously be valuable to ascertain whether microbial metabolites can attenuate spondylitic and arthritic disease (an area of active research by our own group and others). Moreover, our current data set was not large enough to correlate levels of HLA-B27-associated metabolites with changes in either microbiota composition or disease activity, which likely will continue to be a fruitful avenue of research. Nonetheless, our data provide a compelling rationale to investigate whether further targeting gut microbes or gut metabolites themselves to alter the intestinal metabolome may functionally impact SpA pathogenesis and offer innovative treatment modalities for future clinical management of SpA disease.
